{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:09:29Z","timestamp":1784286569441,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2317-z","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"167-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Managing pregnancy in chronic myeloid leukaemia"],"prefix":"10.1007","volume":"94","author":[{"given":"Renuka","family":"Palani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"11","key":"2317_CR1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P (2010) Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029\u20131035","journal-title":"Lancet Oncol"},{"issue":"4","key":"2317_CR2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122(4):515\u2013522","journal-title":"Blood"},{"key":"2317_CR3","unstructured":"(2014) Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation"},{"key":"2317_CR4","unstructured":"(2014) Sprycel (dasatinib): prescribing information. Princeton, NJ: Bristol-Myers Squibb Company"},{"key":"2317_CR5","unstructured":"(2014) Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation"},{"issue":"12","key":"2317_CR6","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1124\/dmd.108.022764","volume":"26","author":"K He","year":"2008","unstructured":"He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ (2008) Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metabol Dispos 26(12):2564\u20132570","journal-title":"Drug Metabol Dispos"},{"key":"2317_CR7","unstructured":"(2013) Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc"},{"key":"2317_CR8","unstructured":"(2014) Inclusig (ponatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals, Inc"},{"key":"2317_CR9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","volume":"24","author":"P Ault","year":"2006","unstructured":"Ault P, Kantarjian H, O\u2019Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J (2006) Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24:1204\u20131208","journal-title":"J Clin Oncol"},{"issue":"2suppl3","key":"2317_CR10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","volume":"40","author":"ML Hensley","year":"2003","unstructured":"Hensley ML, Ford JM (2003) Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40(2suppl3):21\u201325","journal-title":"Semin Hematol"},{"issue":"3","key":"2317_CR11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","volume":"32","author":"M Breccia","year":"2008","unstructured":"Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G (2008) Male patients with chronic myeloid leukemia treated with Imatinib involved in healthy pregnancies: report of five cases. Leuk Res 32(3):519\u2013520","journal-title":"Leuk Res"},{"issue":"4","key":"2317_CR12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","volume":"137","author":"K Ramasamy","year":"2007","unstructured":"Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY (2007) Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 137(4):374\u2013375","journal-title":"Br J Haematol"},{"key":"2317_CR13","doi-asserted-by":"crossref","unstructured":"Iqbal J, Ali Z, Khan AU, Aziz Z (2014) Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma","DOI":"10.3109\/10428194.2013.866662"},{"issue":"10","key":"2317_CR14","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.leukres.2013.07.020","volume":"37","author":"L Zhou","year":"2013","unstructured":"Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH (2013) Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res 37(10):1216\u20131221","journal-title":"Leuk Res"},{"key":"2317_CR15","doi-asserted-by":"crossref","unstructured":"Cortes J, O\u2019Brien S, Ault P, Borthakur G, Jabbour E, Bradley-Garelik B, Debreczeni K, Yang D, Liu D, Kantarjian H (2008) Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112(11). Abstract 3230: Poster presented at: the 50th American Society of Hematology (ASH) Annual Meeting; December 6\u20139, 2008; San Francisco, USA","DOI":"10.1182\/blood.V112.11.3230.3230"},{"issue":"3","key":"2317_CR16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/10428194.2013.811240","volume":"55","author":"M Gentile","year":"2014","unstructured":"Gentile M, Guido M, Lucia E, Vigna E, Mazzone C, Recchia AG, Morabito F (2014) Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leuk Lymphoma 55(3):709\u2013710","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2317_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00404-010-1501-6","volume":"283","author":"H Oweini","year":"2011","unstructured":"Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A (2011) Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 283(1):133\u2013134","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"2317_CR18","doi-asserted-by":"crossref","first-page":"e2014028","DOI":"10.4084\/mjhid.2014.028","volume":"6","author":"E Abrusezze","year":"2014","unstructured":"Abrusezze E, Trawinska MM, Perrotti AP, De Fabritiis P (2014) Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 6(1):e2014028","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2317_CR19","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfied A, Kantarjian H, Pilot R, Rosti G, Apperly J (2008) The effects of Imatinib on pregnancy outcome. Blood 111:5505\u20135508","journal-title":"Blood"},{"key":"2317_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0306-3356(21)00157-6","volume":"13","author":"JJ Laferla","year":"1986","unstructured":"Laferla JJ (1986) Spontaneous abortion. Clin Obstet Gynaecol 13:105\u2013114","journal-title":"Clin Obstet Gynaecol"},{"key":"2317_CR21","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1242\/dev.124.14.2691","volume":"124","author":"P Soriano","year":"1997","unstructured":"Soriano P (1997) The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124:2691\u20132700","journal-title":"Development"},{"key":"2317_CR22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/sj.ejhg.5201872","volume":"15","author":"SB Bleyl","year":"2007","unstructured":"Bleyl SB, Moshrefi A, Shaw GM, Saijoh Y, Schoenwolf GC, Pennacchio LA, Slavotinek AM (2007) Candidate genes for congenital diaphragmatic hernia from animal models: sequencing of FOG2 and PDGFR alpha reveals rare variants in diaphragmatic hernia patients. Eur J Hum Genet 15:950\u2013958","journal-title":"Eur J Hum Genet"},{"key":"2317_CR23","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1242\/dev.127.21.4519","volume":"127","author":"T Sun","year":"2000","unstructured":"Sun T, Jayatilake D, Afink GB, Ataliotis P, Nist\u00e9r M, Richardson WD, Smith HK (2000) A human YAC transgene rescues craniofacial and neural tube development in PDGFR alpha knockout mice and uncovers a role for PDGFR alpha in prenatal lung growth. Development 127:4519\u20134529","journal-title":"Development"},{"key":"2317_CR24","doi-asserted-by":"crossref","unstructured":"Bayraktar S, Morency B, Escalon MP (2010) Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case Reports Online Publication","DOI":"10.1136\/bcr.05.2010.2975"},{"key":"2317_CR25","doi-asserted-by":"crossref","first-page":"136252","DOI":"10.1155\/2010\/136252","volume":"2010","author":"M Conchon","year":"2010","unstructured":"Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Lacer PE, Bendit I (2010) Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010:136252","journal-title":"Adv Hematol"},{"issue":"9","key":"2317_CR26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3109\/10428194.2010.497982","volume":"51","author":"T Kroll","year":"2010","unstructured":"Kroll T, Ames MB, Pruett JA, Fenske TS (2010) Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 51(9):1751\u20131753","journal-title":"Leuk Lymphoma"},{"issue":"5\u20136","key":"2317_CR27","first-page":"128","volume":"10","author":"G Dine","year":"2013","unstructured":"Dine G, Levert M, Rehn Y, Ali AN, Brahimi S, Gaillard B, Bocq I, Fumagalli G (2013) Two successful successive pregnancies in a woman with CML treated with dasatinib and temporary peg-interferon. J US-China Med Sci 10(5\u20136):128\u2013133","journal-title":"J US-China Med Sci"},{"issue":"7","key":"2317_CR28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","volume":"23","author":"P Berveiller","year":"2012","unstructured":"Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, Chapuis N, Tsatsaris V (2012) A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs 23(7):754\u2013757","journal-title":"Anti-Cancer Drugs"},{"key":"2317_CR29","doi-asserted-by":"crossref","unstructured":"Conchon M, Sanabani SS, Bendit I (2009) Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 42(2)","DOI":"10.1186\/1756-8722-2-42"},{"issue":"8","key":"2317_CR30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1684\/bdc.2010.1136","volume":"97","author":"G Etienne","year":"2010","unstructured":"Etienne G, Milpied B, R\u00e9a D, Rigal-Huguet F, Tulliez M, Nicolini FE (2010) French Intergroup of CML (Fi-LMC group). Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group). Bull Cancer 97(8):997\u20131009","journal-title":"Bull Cancer"},{"issue":"6","key":"2317_CR31","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","volume":"50","author":"HG Goh","year":"2009","unstructured":"Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH, Kweon IY (2009) Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukaemia: implications for intermittent imatinib therapy. Leuk Lymphoma 50(6):944\u2013951","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2317_CR32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","volume":"116","author":"A Kuwabara","year":"2010","unstructured":"Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D (2010) Poor outcome after reintroduction of imatinib in patients with CML who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116(6):1014\u20131016","journal-title":"Blood"},{"issue":"2","key":"2317_CR33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2141.1992.tb08202.x","volume":"81","author":"MR Baer","year":"1992","unstructured":"Baer MR, Ozer H, Foon KA (1992) Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 81(2):167\u2013169","journal-title":"Br J Haematol"},{"key":"2317_CR34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.9876","volume":"69","author":"AA Mubarak","year":"2002","unstructured":"Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, Al-Hassan A (2002) Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-a in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 69:115\u2013118","journal-title":"Am J Hematol"},{"key":"2317_CR35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1515\/JPM.2000.047","volume":"28","author":"M Hiratsuka","year":"2000","unstructured":"Hiratsuka M, Minakami H, Koshizuka S, Sato I (2000) Administration of interferon-a during pregnancy: effect on fetus. J Perinat Med 28:372\u2013376","journal-title":"J Perinat Med"},{"key":"2317_CR36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000057634","volume":"107","author":"B Vantroyen","year":"2002","unstructured":"Vantroyen B, Vanstraelen D (2002) Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha 2a and no treatment. A comprehensive analysis of the literature. Acta Hematol 107:158\u2013169","journal-title":"Acta Hematol"},{"key":"2317_CR37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.20476","volume":"81","author":"AC Regierer","year":"2006","unstructured":"Regierer AC, Schulz CO, Kuehnhardt D, Flath B, Possinger K (2006) Interferon a\u2014therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 81:149\u2013156","journal-title":"Am J Hematol"},{"key":"2317_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijgo.2003.11.014","volume":"85","author":"S Al Bahar","year":"2004","unstructured":"Al Bahar S, Pandita R, Nath SV (2004) Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynecol Obstet 85:281\u2013282","journal-title":"Int J Gynecol Obstet"},{"key":"2317_CR39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<101::AID-AJH23>3.0.CO;2-D","volume":"59","author":"M Kuroiwa","year":"1998","unstructured":"Kuroiwa M, Gondo H, Ashida K, Kamimura T, Miyamoto T, Niho Y, Tsukimori K, Nakano H, Ohga S (1998) Interferon alpha therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 59:101\u2013102","journal-title":"Am J Hematol"},{"key":"2317_CR40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/sj.leu.2402168","volume":"15","author":"C Thauvin Robinet","year":"2001","unstructured":"Thauvin Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, Casasnovas RO, Douvier S, Nivelon-Chevallier A (2001) Exposure to hydroxyurea during pregnancy: a case series. Leukemia 15:1309\u20131311","journal-title":"Leukemia"},{"key":"2317_CR41","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/sj.leu.2402494","volume":"16","author":"SA Fadilah","year":"2002","unstructured":"Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M (2002) Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 16:1202\u20131203","journal-title":"Leukemia"},{"key":"2317_CR42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","volume":"27","author":"MA Russel","year":"2007","unstructured":"Russel MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ (2007) Imatinib mesylate and metabolite concentration in maternal blood, umbelical cord blood, placenta and breast milk. J Perinatol 27:241\u2013243","journal-title":"J Perinatol"},{"issue":"2","key":"2317_CR43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","volume":"280","author":"R Ali","year":"2009","unstructured":"Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, Yorulmaz H, Tunali A (2009) Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 280(2):169\u2013175, 2008","journal-title":"Arch Gynecol Obstet"},{"key":"2317_CR44","unstructured":"(2006) Bristol-Myers Squibb Canada. HYDREA\u00ae product monograph. Montreal, Quebec"},{"issue":"3","key":"2317_CR45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/089033440001600308","volume":"16","author":"AR Kumar","year":"2000","unstructured":"Kumar AR, Hale TW, Mock RE (2000) Transfer of interferon alfa into human breast milk. J Hum Lact 16(3):226\u2013228","journal-title":"J Hum Lact"},{"key":"2317_CR46","doi-asserted-by":"crossref","unstructured":"Lichtman MLJ (2001) 6th ed. Vol. 1047. New York, NY: McGraw-Hill. Acute myelogenous leukemia. Williams Hematology","DOI":"10.1038\/npg.els.0002180"},{"key":"2317_CR47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/0002-9378(58)90659-8","volume":"75","author":"WT Sheehy","year":"1958","unstructured":"Sheehy WT (1958) An evaluation of the effect of pregnancy on chronic granulocytic leukaemia. Am J Obstet Gynecol 75:788","journal-title":"Am J Obstet Gynecol"},{"key":"2317_CR48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jjco\/hyh038","volume":"34","author":"R Ali","year":"2004","unstructured":"Ali R, Ozkalemka\u015f F, Ozkocaman V, Oz\u00e7elik T, Ozan U, Kimya Y, Tunali A (2004) Successful pregnancy and delivery in patient with CML and management of CML with leukapheresis during pregnancy. Jpn J Clin Oncol 34:215\u2013217","journal-title":"Jpn J Clin Oncol"},{"key":"2317_CR49","first-page":"147","volume":"65","author":"R Klaasen","year":"2007","unstructured":"Klaasen R, de-Jong P, Wijermans PW (2007) Successful management of chronic myeloid leukemia with leucapheresis during a twin pregnancy. Neth J Med 65:147\u2013149","journal-title":"Neth J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2317-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2317-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2317-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T21:50:28Z","timestamp":1651614628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2317-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":49,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2317-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}